Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Chief Financial Officer | May 18, 2026 | May 20, 2026 |
| Odonate Therapeutics, Inc.ODT · Entity 132524 | Chief Financial Officer | November 17, 2021 | November 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,144 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 116,144 · Balance 116,144 F1: Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.28 · Expires 2036-05-18 | Direct | 70,230 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Grant · Acquired 70,230 · Balance 70,230 F2: 33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly installments over the following 2 years. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date.
F2: 33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly installments over the following 2 years.
Odonate Therapeutics, Inc.
Report date November 17, 2021 · Filed November 19, 2021
Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP, TANG CAPITAL MANAGEMENT LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 12,767,435 |
Last balance in matching sequence
After 2021-11-19 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
8 source rowsRow 1 · 2021-11-17 · Sale · Disposed 468,849 · Balance 15,045,717 F1: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 2 · 2021-11-17 · Sale · Disposed 31,151 · Balance 15,014,566 F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 3 · 2021-11-17 · Sale · Disposed 500,000 · Balance 14,514,566 F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 4 · 2021-11-17 · Sale · Disposed 287,577 · Balance 14,226,989 F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 5 · 2021-11-18 · Sale · Disposed 212,423 · Balance 14,014,566 F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 6 · 2021-11-18 · Sale · Disposed 500,000 · Balance 13,514,566 F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 7 · 2021-11-18 · Sale · Disposed 381,842 · Balance 13,132,724 F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 8 · 2021-11-19 · Sale · Disposed 365,289 · Balance 12,767,435 F9: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein.
F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005.
F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07.
F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33.
F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16.
F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99.
F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001.
F9: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LA JOLLA PHARMACEUTICAL CO
Report date August 22, 2022 · Filed August 24, 2022
Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.63 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-22 · Disposition to issuer · Disposed 1,675 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-22 · Disposition to issuer · Disposed 169 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-22 · Disposition to issuer · Disposed 185 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-22 · Disposition to issuer · Disposed 177 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.37 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-08-22 · Disposition to issuer · Disposed 173 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-08-22 · Disposition to issuer · Disposed 185 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-08-22 · Disposition to issuer · Disposed 236 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.19 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-08-22 · Disposition to issuer · Disposed 236 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Series C-1 (2) Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBY LP | 0 |
Reported balance
After 2022-08-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-08-22 · Other · Disposed 3,519.315 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-12 Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price. F3: The Shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time").
F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
F3: The Shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP.
F4: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-12 Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2020 Filed Feb 2, 2021 17:18 UTC Amendment | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,648 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000920465-21-000004 · wf-form4a_161230428119904.xml · derivative · entry 2 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,648 Underlying: Common Stock · 1,648 shares Expires 2030-12-31 F2 · shares: This is adjusted to 1,648 from 171 in Form 4 filed on 1/5/21 F4 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years. F2 · derivative.underlying_shares: This is adjusted to 1,648 from 171 in Form 4 filed on 1/5/21 F2 · balance_after: This is adjusted to 1,648 from 171 in Form 4 filed on 1/5/21 Read SEC document |
| December 31, 2020 Filed Feb 2, 2021 17:18 UTC Amendment | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 1,648 | $3.30 | $5,435.10 |
DisclosureSEC source: 0000920465-21-000004 · wf-form4a_161230428119904.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,435 F1 · kind: These shares were acquired on 12/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · shares: This is adjusted to 1,648 from 171 in Form 4 filed on 1/5/21 F3 · balance_after: This is adjusted to 2,435 from 958 in Form 4 filed on 1/5/21 Read SEC document |
| December 23, 2020 Filed Dec 23, 2020 21:41 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 75,784 | $15.71 | $1,190,415.07 |
DisclosureSEC source: 0001209191-20-065024 · doc4.xml · nonDerivative · entry 5 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 15,514,566 F6 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.53 to $15.79. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| December 23, 2020 Filed Dec 23, 2020 21:41 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 63,354 | $15.43 | $977,438.18 |
DisclosureSEC source: 0001209191-20-065024 · doc4.xml · nonDerivative · entry 4 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 15,438,782 F5 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.15 to $15.60. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:41 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 36,646 | $15.17 | $555,820.88 |
DisclosureSEC source: 0001209191-20-065024 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 15,375,428 F4 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $14.69 to $15.25. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:41 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 37,856 | $14.58 | $551,766.34 |
DisclosureSEC source: 0001209191-20-065024 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 15,338,782 F3 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $14.05 to $14.75. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:41 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 62,144 | $14.58 | $905,767.44 |
DisclosureSEC source: 0001209191-20-065024 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 15,300,926 F1 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $14.22 to $14.75. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 6 herein. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 16:22 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock · Derivative | 147 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0000920465-20-000168 · wf-form4_160815375345674.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147 Underlying: Common Stock · 147 shares Expires 2030-12-15 F3 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 16:22 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 147 | $3.83 | $562.28 |
DisclosureSEC source: 0000920465-20-000168 · wf-form4_160815375345674.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 787 F1 · kind: These shares were acquired on 12/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 16:01 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 43 | $0.00 Strike: $15.19 | $0.00 |
DisclosureSEC source: 0001209191-20-064023 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43 Underlying: Common Stock · 43 shares Expires 2030-12-15 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 16:01 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantCommon Stock | 43 | $12.91 | $555.13 |
DisclosureSEC source: 0001209191-20-064023 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,105 F1 · kind: These shares were acquired on 12/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 16:24 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 52,191 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0000920465-20-000166 · wf-form4_160798107874420.xml · derivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,191 Underlying: Common Stock · 52,191 shares Expires 2030-12-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:06 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,639 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0001209191-20-062694 · doc4.xml · derivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,639 Underlying: Common Stock · 22,639 shares Expires 2030-12-08 F1 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 16:21 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 134 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0000920465-20-000160 · wf-form4_160694407414311.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134 Underlying: Common Stock · 134 shares Expires 2030-11-30 F3 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 16:21 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 134 | $4.23 | $566.15 |
DisclosureSEC source: 0000920465-20-000160 · wf-form4_160694407414311.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640 F1 · kind: These shares were acquired on 11/30/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 16:02 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 45 | $0.00 Strike: $15.02 | $0.00 |
DisclosureSEC source: 0001209191-20-061108 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45 Underlying: Common Stock · 45 shares Expires 2030-11-30 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 16:02 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantCommon Stock | 45 | $12.77 | $574.65 |
DisclosureSEC source: 0001209191-20-061108 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,062 F1 · kind: These shares were acquired on 11/30/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 16:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 141 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0000920465-20-000158 · wf-form4_160564756822438.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141 Underlying: Common Stock · 141 shares Expires 2030-11-13 F3 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 16:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 141 | $3.98 | $560.90 |
DisclosureSEC source: 0000920465-20-000158 · wf-form4_160564756822438.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506 F1 · kind: These shares were acquired on 11/13/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 16:06 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 46 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001209191-20-058698 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46 Underlying: Common Stock · 46 shares Expires 2030-11-13 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 16:06 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantCommon Stock | 46 | $12.20 | $561.20 |
DisclosureSEC source: 0001209191-20-058698 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,017 F1 · kind: These shares were acquired on 11/13/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 16:06 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 46 | $0.00 Strike: $14.41 | $0.00 |
DisclosureSEC source: 0001209191-20-056586 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46 Underlying: Common Stock · 46 shares Expires 2030-10-30 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 16:06 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantCommon Stock | 46 | $12.25 | $563.50 |
DisclosureSEC source: 0001209191-20-056586 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,971 F1 · kind: These shares were acquired on 10/30/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 30, 2020 Filed Nov 5, 2020 16:59 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 196 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000920465-20-000156 · wf-form4_160461358133519.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196 Underlying: Common Stock · 196 shares Expires 2030-10-30 F3 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 30, 2020 Filed Nov 5, 2020 16:59 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 196 | $2.89 | $566.44 |
DisclosureSEC source: 0000920465-20-000156 · wf-form4_160461358133519.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365 F1 · kind: These shares were acquired on 10/30/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:14 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 169 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0000920465-20-000151 · wf-form4_160315647937407.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169 Underlying: Common Stock · 169 shares Expires 2030-10-15 F3 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:14 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 169 | $3.32 | $561.08 |
DisclosureSEC source: 0000920465-20-000151 · wf-form4_160315647937407.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169 F1 · kind: These shares were acquired on 10/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 16:04 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 42 | $0.00 Strike: $15.70 | $0.00 |
DisclosureSEC source: 0001209191-20-055254 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42 Underlying: Common Stock · 42 shares Expires 2030-10-15 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 16:04 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantCommon Stock | 42 | $13.35 | $560.70 |
DisclosureSEC source: 0001209191-20-055254 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,925 F1 · kind: These shares were acquired on 10/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 16:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50 | $0.00 Strike: $13.43 | $0.00 |
DisclosureSEC source: 0001209191-20-053052 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50 Underlying: Common Stock · 50 shares Expires 2030-09-30 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 16:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantCommon Stock | 50 | $11.42 | $571.00 |
DisclosureSEC source: 0001209191-20-053052 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,883 F1 · kind: These shares were acquired on 09/30/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 20:01 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 10,882 | $13.85 | $150,698.29 |
DisclosureSEC source: 0001209191-20-052437 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Lemkey John G · CIK 0001495904 · Chief Operating Officer Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 15,238,782 F3 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.66 to $13.90. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:01 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 100,000 | $13.06 | $1,305,710.00 |
DisclosureSEC source: 0001209191-20-052437 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Lemkey John G · CIK 0001495904 · Chief Operating Officer Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 15,227,900 F1 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $12.71 to $13.19. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 herein. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:13 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 43 | $0.00 Strike: $15.37 | $0.00 |
DisclosureSEC source: 0001209191-20-050877 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43 Underlying: Common Stock · 43 shares Expires 2030-09-15 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:13 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantCommon Stock | 43 | $13.06 | $561.58 |
DisclosureSEC source: 0001209191-20-050877 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,833 F1 · kind: These shares were acquired on 09/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 09, 2020 Filed Sep 9, 2020 18:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 78,369 | $4.03 | $316,046.50 |
DisclosureSEC source: 0001209191-20-049871 · doc4.xml · nonDerivative · entry 4 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 9,405,490 F5 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.94 to $4.10. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| September 09, 2020 Filed Sep 9, 2020 18:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 48,296 | $4.01 | $193,893.95 |
DisclosureSEC source: 0001209191-20-049871 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 9,327,121 F4 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.91 to $4.10. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 84,152 | $3.90 | $328,529.41 |
DisclosureSEC source: 0001209191-20-049871 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 9,278,825 F3 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.82 to $4.01. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 18:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 67,552 | $3.82 | $258,359.38 |
DisclosureSEC source: 0001209191-20-049871 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 9,194,673 F1 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.66 to $3.97. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 5 herein. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 42 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001209191-20-049097 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42 Underlying: Common Stock · 42 shares Expires 2030-08-31 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantCommon Stock | 42 | $13.73 | $576.66 |
DisclosureSEC source: 0001209191-20-049097 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,790 F1 · kind: These shares were acquired on 08/31/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 12:17 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 1,052,631 | $14.25 | $14,999,991.75 |
DisclosureSEC source: 0001209191-20-048868 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Lemkey John G · CIK 0001495904 · Chief Operating Officer Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 15,127,900 F1 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F1 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 16:49 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 168,669 | $3.88 | $653,693.58 |
DisclosureSEC source: 0001209191-20-046812 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 9,127,121 F4 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.685 to $3.95. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 16:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18 | $0.00 Strike: $36.13 | $0.00 |
DisclosureSEC source: 0001209191-20-047169 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18 Underlying: Common Stock · 18 shares Expires 2030-08-14 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 16:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantCommon Stock | 18 | $30.71 | $552.78 |
DisclosureSEC source: 0001209191-20-047169 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,748 F1 · kind: These shares were acquired on 08/14/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 16:49 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 219,465 | $3.65 | $800,586.37 |
DisclosureSEC source: 0001209191-20-046812 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 8,958,452 F3 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.71. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 16:49 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 43,513 | $3.47 | $150,820.41 |
DisclosureSEC source: 0001209191-20-046812 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 8,738,987 F1 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.415 to $3.54. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 4 herein. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 16:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18 | $0.00 Strike: $36.37 | $0.00 |
DisclosureSEC source: 0001209191-20-044663 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18 Underlying: Common Stock · 18 shares Expires 2030-07-31 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 16:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantCommon Stock | 18 | $30.91 | $556.38 |
DisclosureSEC source: 0001209191-20-044663 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,730 F1 · kind: These shares were acquired on 07/31/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:04 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17 | $0.00 Strike: $41.17 | $0.00 |
DisclosureSEC source: 0001209191-20-042781 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17 Underlying: Common Stock · 17 shares Expires 2030-07-15 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.